CMPX
Compass Therapeutics·NASDAQ
--
--(--)
--
--(--)
CMPX fundamentals
During Q4 2025, Compass Therapeutics (CMPX) reported revenue of --, a YoY change of 0.00%. Net income was -15.72M, a YoY change of -4.54%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q1,2019 | Q2,2019 | Q3,2019 | Q4,2019 | Q1,2020 | Q2,2020 | Q3,2020 | Q4,2020 | Q1,2021 | Q2,2021 | Q3,2021 | Q4,2021 | Q1,2022 | Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Apr 1, 2018 | Jul 1, 2018 | Oct 1, 2018 | Jan 1, 2019 | Apr 1, 2019 | Jul 1, 2019 | Oct 1, 2019 | Jan 1, 2020 | Jan 1, 2021 | Apr 1, 2021 | Jul 1, 2021 | Oct 1, 2021 | Jan 1, 2022 | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Jun 30, 2018 | Sep 30, 2018 | Dec 31, 2018 | Mar 31, 2019 | Jun 30, 2019 | Sep 30, 2019 | Dec 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Jun 30, 2021 | Sep 30, 2021 | Dec 31, 2021 | Mar 31, 2022 | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | 850.00K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Sales and Services Revenue | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | 850.00K -- | 0 -- | 0 -- | -- -- | 0 -100.00% | 0 -- | 0 -- | -- -- |
Cost of Revenue | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | 7.89K -- | 7.79K -- | 9.27K -- | 7.81K -- | 10.32K +30.71% | 7.15K -8.14% | 10.24K +10.48% | 4.40K -43.71% | 7.34M +71028.13% | 55.69M +778658.22% | 5.85M +57079.14% | 12.96M +294556.66% | 7.18M -2.14% | 8.99M -83.86% | 12.60M +115.20% | 12.82M -1.09% | 9.71M +35.21% | 13.34M +48.40% | 11.93M -5.33% | 15.39M +20.09% | 12.77M +31.50% | 15.89M +19.18% | 12.24M +2.62% | 16.57M +7.67% | 17.97M +40.69% | 21.07M +32.53% | 15.82M +29.23% | 17.99M +8.54% | 72.84M -- |
Selling, General and Administrative Expenses | 7.89K -- | 7.79K -- | 9.27K -- | 7.81K -- | 10.32K +30.71% | 7.15K -8.14% | 10.24K +10.48% | 4.40K -43.71% | 2.63M +25437.89% | 2.17M +30189.47% | 2.70M +26272.34% | 3.43M +77821.78% | 2.77M +5.01% | 3.13M +44.28% | 2.81M +3.96% | 2.96M -13.63% | 3.07M +11.06% | 3.11M -0.35% | 3.10M +10.26% | 2.97M +0.24% | 3.25M +5.69% | 4.72M +51.61% | 3.63M +17.19% | 3.54M +19.18% | 4.91M +51.23% | 4.65M -1.48% | 2.99M -17.54% | 4.32M +22.12% | 16.87M -- |
General and Administrative Expenses | -- -- | -- -- | -- -- | 32.76K -- | -- -- | -- -- | -- -- | 32.10K -2.00% | -- -- | -- -- | -- -- | 10.93M +33935.20% | -- -- | -- -- | -- -- | 11.66M +6.69% | -- -- | -- -- | 3.10M -- | 2.97M -74.55% | 3.25M -- | 4.72M -- | 3.63M +17.19% | 3.54M +19.18% | 4.91M +51.23% | 4.65M -1.48% | 2.99M -17.54% | 4.32M +22.12% | 16.87M -- |
Research and Development Expenses | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 4.70M -- | 53.52M -- | 3.15M -- | 9.57M -- | 4.42M -6.14% | 5.86M -89.05% | 9.79M +210.43% | 9.93M +3.70% | 6.64M +50.35% | 10.22M +74.39% | 8.83M -9.80% | 12.43M +25.16% | 9.52M +43.45% | 11.17M +9.30% | 8.61M -2.48% | 13.04M +4.93% | 13.05M +37.09% | 16.41M +46.90% | 12.83M +48.93% | 13.67M +4.86% | 55.97M -- |
Loss on Disposal of Assets | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -42.00K -- | -- -- | -- -- | -- -- | -70.00K -66.67% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Income | -7.89K -- | -7.79K -- | -9.27K -- | -7.81K -- | -10.32K -30.71% | -7.15K +8.14% | -10.24K -10.48% | -4.40K +43.71% | -7.34M -71028.13% | -55.69M -778658.22% | -5.85M -57079.14% | -12.96M -294556.66% | -7.18M +2.14% | -8.99M +83.86% | -12.60M -115.20% | -12.82M +1.09% | -9.71M -35.21% | -13.34M -48.40% | -11.93M +5.33% | -15.39M -20.09% | -12.77M -31.50% | -15.04M -12.81% | -12.24M -2.62% | -16.57M -7.67% | -17.97M -40.69% | -21.07M -40.02% | -15.82M -29.23% | -17.99M -8.54% | -72.84M -- |
Non-Operating Income (Loss) | -580 -- | -771 -- | -875 -- | -1.05K -- | -1.14K -97.24% | -1.25K -62.39% | -1.44K -65.03% | -1.54K -46.20% | -83.00K -7155.24% | -102.00K -8046.96% | -121.00K -8279.50% | -35.00K -2175.68% | 20.00K +124.10% | 493.00K +583.33% | 623.00K +614.88% | 1.22M +3597.14% | 1.87M +9270.00% | 2.06M +317.65% | 1.96M +214.93% | 1.98M +61.60% | 1.98M +5.82% | 1.97M -4.37% | 1.76M -10.40% | 1.54M -22.09% | 1.33M -32.78% | 1.19M -39.82% | 1.56M -11.38% | 2.27M +47.57% | 6.35M -- |
Other Non-Operating Income (Loss) | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 44.00K -- | -- -- | -44.00K -- | -- -- | 20.00K -54.55% | 69.00K -- | -- -- | -70.00K -- | 1.87M +9270.00% | 2.06M +2884.06% | 1.96M -- | 1.98M +2925.71% | 1.98M +5.82% | 1.97M -4.37% | 1.76M -10.40% | -5.71M -388.62% | 1.33M -32.78% | 1.19M -39.82% | 1.56M -11.38% | -4.08M +28.60% | -- -- |
Net Interest Expense | 580 -- | 771 -- | 875 -- | 1.05K -- | 1.14K +97.24% | 1.25K +62.39% | 1.44K +65.03% | 1.54K +46.20% | 127.00K +11001.40% | 102.00K +8046.96% | 77.00K +5232.41% | 35.00K +2175.68% | -- -- | -424.00K -515.69% | -623.00K -909.09% | -1.29M -3797.14% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -7.25M -- | -- -- | -- -- | -- -- | -6.35M +12.41% | -- -- |
Interest Expense | 580 -- | 771 -- | 875 -- | 1.05K -- | 1.14K +97.24% | 1.25K +62.39% | 1.44K +65.03% | 1.54K +46.20% | 142.00K +12312.59% | 111.00K +8765.81% | 78.00K +5301.66% | 39.00K +2435.76% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Interest Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 15.00K -- | 9.00K -- | 1.00K -- | 4.00K -- | -- -- | 424.00K +4611.11% | 623.00K +62200.00% | 1.29M +32250.00% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 7.25M -- | -- -- | -- -- | -- -- | 6.35M -12.41% | -- -- |
Pretax Income From Continuing Operations | -8.47K -- | -8.56K -- | -10.14K -- | -8.87K -- | -11.46K -35.26% | -8.40K +1.79% | -11.68K -15.18% | -5.94K +33.04% | -7.42M -64653.10% | -55.79M -663841.45% | -5.97M -51047.06% | -12.99M -218801.62% | -7.16M +3.50% | -8.49M +84.78% | -11.97M -100.42% | -11.59M +10.77% | -7.84M -9.42% | -11.28M -32.78% | -9.96M +16.79% | -13.41M -15.71% | -10.79M -37.64% | -13.08M -15.94% | -10.48M -5.19% | -15.03M -12.06% | -16.63M -54.19% | -19.88M -52.04% | -14.26M -36.05% | -15.72M -4.54% | -66.49M -- |
Income Tax Expense | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 13.00K -- | 0 -- | -13.00K -- | 0 -- | 0 -100.00% | -- -- | 0 +100.00% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income | -8.47K -- | -8.56K -- | -10.14K -- | -8.87K -- | -11.46K -35.26% | -8.40K +1.79% | -11.68K -15.18% | -5.94K +33.04% | -7.42M -64653.10% | -55.80M -663996.16% | -5.97M -51047.06% | -12.98M -218582.61% | -7.16M +3.50% | -8.49M +84.78% | -11.97M -100.42% | -11.59M +10.68% | -7.84M -9.42% | -11.28M -32.78% | -9.96M +16.79% | -13.41M -15.71% | -10.79M -37.64% | -13.08M -15.94% | -10.48M -5.19% | -15.03M -12.06% | -16.63M -54.19% | -19.88M -52.04% | -14.26M -36.05% | -15.72M -4.54% | -66.49M -- |
Net Income Attributable to Owners of the Company | -8.47K -- | -8.56K -- | -10.14K -- | -8.87K -- | -11.46K -35.26% | -8.40K +1.79% | -11.68K -15.18% | -5.94K +33.04% | -7.42M -64653.10% | -55.80M -663996.16% | -5.97M -51047.06% | -12.98M -218582.61% | -7.16M +3.50% | -8.49M +84.78% | -11.97M -100.42% | -11.59M +10.68% | -7.84M -9.42% | -11.28M -32.78% | -9.96M +16.79% | -13.41M -15.71% | -10.79M -37.64% | -13.08M -15.94% | -10.48M -5.19% | -15.03M -12.06% | -16.63M -54.19% | -19.88M -52.04% | -14.26M -36.05% | -15.72M -4.54% | -66.49M -- |
Net Income Attributable to Common Stockholders | -8.47K -- | -8.56K -- | -10.14K -- | -8.87K -- | -11.46K -35.26% | -8.40K +1.79% | -11.68K -15.18% | -5.94K +33.04% | -7.42M -64653.10% | -55.80M -663996.16% | -5.97M -51047.06% | -12.98M -218582.61% | -7.16M +3.50% | -8.49M +84.78% | -11.97M -100.42% | -11.59M +10.68% | -7.84M -9.42% | -11.28M -32.78% | -9.96M +16.79% | -13.41M -15.71% | -10.79M -37.64% | -13.08M -15.94% | -10.48M -5.19% | -15.03M -12.06% | -16.63M -54.19% | -19.88M -52.04% | -14.26M -36.05% | -15.72M -4.54% | -66.49M -- |
Other Comprehensive Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | 0 -- | -- -- | -512.00K -- | -129.00K -- | 339.00K -- | 156.00K -- | -361.00K +29.49% | 77.00K +159.69% | 467.00K +37.76% | -127.00K -181.41% | -1.00K +99.72% | 577.00K +649.35% | -276.00K -159.10% | -20.00K +84.25% | 18.00K +1900.00% | 66.00K -88.56% | 6.00K +102.17% | 70.00K -- |
Total Comprehensive Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -55.80M -- | -5.97M -- | -12.98M -- | -7.16M -- | -9.01M +83.86% | -12.10M -102.58% | -11.26M +13.30% | -7.68M -7.25% | -11.64M -29.24% | -9.89M +18.32% | -12.95M -15.04% | -10.91M -42.09% | -13.08M -12.36% | -9.90M -0.17% | -15.31M -18.23% | -16.65M -52.58% | -19.86M -51.89% | -14.19M -43.31% | -15.71M -2.62% | -66.42M -- |
Total Comprehensive Income Attributable to Owners of the Company | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -55.80M -- | -5.97M -- | -12.98M -- | -7.16M -- | -9.01M +83.86% | -12.10M -102.58% | -11.26M +13.30% | -7.68M -7.25% | -11.64M -29.24% | -9.89M +18.32% | -12.95M -15.04% | -10.91M -42.09% | -13.08M -12.36% | -9.90M -0.17% | -15.31M -18.23% | -16.65M -52.58% | -19.86M -51.89% | -14.19M -43.31% | -15.71M -2.62% | -66.42M -- |
Basic EPS | 0 -- | 0 -- | 0 -- | -- -- | 0 -- | 0 -- | 0 -- | -- -- | -0.14 -- | -1.07 -- | -0.1 -- | -0.13 -- | -0.07 +50.00% | -0.08 +92.52% | -0.12 -20.00% | -0.09 +30.77% | -0.06 +14.29% | -0.09 -12.50% | -0.08 +33.33% | -0.11 -22.22% | -0.08 -33.33% | -0.1 -11.11% | -0.08 -- | -0.11 -- | -0.12 -50.00% | -0.14 -40.00% | -0.08 -- | -0.09 +18.18% | -0.43 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.08 -- | -- -- | -0.08 -- | -0.1 -- | -0.08 -- | -- -- | -0.12 -50.00% | -0.14 -40.00% | -0.08 -- | -- -- | -- -- |
Diluted EPS | 0 -- | 0 -- | 0 -- | -- -- | 0 -- | 0 -- | 0 -- | -- -- | -0.14 -- | -1.07 -- | -0.1 -- | -- -- | -0.07 +50.00% | -0.08 +92.52% | -0.12 -20.00% | -- -- | -0.06 +14.29% | -0.09 -12.50% | -0.08 +33.33% | -- -- | -0.08 -33.33% | -0.1 -11.11% | -0.08 -- | -- -- | -0.12 -50.00% | -0.14 -40.00% | -0.08 -- | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.08 -- | -- -- | -0.08 -- | -0.1 -- | -0.08 -- | -- -- | -0.12 -50.00% | -0.14 -40.00% | -0.08 -- | -- -- | -- -- |
You can ask Aime
What is Compass Therapeutics's gross profit margin?What guidance did Compass Therapeutics's management provide for the next earnings period?What factors drove the changes in Compass Therapeutics's revenue and profit?What is the market's earnings forecast for Compass Therapeutics next quarter?What were the key takeaways from Compass Therapeutics’s earnings call?What were the key takeaways from Compass Therapeutics's earnings call?Did Compass Therapeutics beat or miss consensus estimates last quarter?What does Compass Therapeutics do and what are its main business segments?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
